These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 32393197)

  • 1. Neoadjuvant chemotherapy followed by curative-intent surgery for perihilar cholangiocarcinoma based on its anatomical resectability classification and lymph node status.
    Kuriyama N; Usui M; Gyoten K; Hayasaki A; Fujii T; Iizawa Y; Kato H; Murata Y; Tanemura A; Kishiwada M; Sakurai H; Mizuno S; Isaji S
    BMC Cancer; 2020 May; 20(1):405. PubMed ID: 32393197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of neoadjuvant chemotherapy based on our resectability criteria for locally advanced perihilar cholangiocarcinoma.
    Gyoten K; Kuriyama N; Maeda K; Ito T; Hayasaki A; Fujii T; Iizawa Y; Tanemura A; Murata Y; Kishiwada M; Mizuno S
    Langenbecks Arch Surg; 2023 Jul; 408(1):261. PubMed ID: 37392289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant gemcitabine monotherapy for resectable perihilar cholangiocarcinoma with lymph node involvement: a propensity score matching analysis.
    Mizuno T; Ebata T; Yokoyama Y; Igami T; Sugawara G; Yamaguchi J; Nagino M
    Surg Today; 2017 Feb; 47(2):182-192. PubMed ID: 27194019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High tumor budding is a strong predictor of poor prognosis in the resected perihilar cholangiocarcinoma patients regardless of neoadjuvant therapy, showing survival similar to those without resection.
    Ito T; Kuriyama N; Kozuka Y; Komatsubara H; Ichikawa K; Noguchi D; Hayasaki A; Fujii T; Iizawa Y; Kato H; Tanemura A; Murata Y; Kishiwada M; Mizuno S; Usui M; Sakurai H; Isaji S
    BMC Cancer; 2020 Mar; 20(1):209. PubMed ID: 32164621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the Clinical Applicability of the European Staging System for Perihilar Cholangiocarcinoma.
    Ismael HN; Loyer E; Kaur H; Conrad C; Vauthey JN; Aloia T
    J Gastrointest Surg; 2016 Apr; 20(4):741-7. PubMed ID: 26801328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Gemcitabine Plus S1 Neoadjuvant Chemotherapy on Borderline Resectable Perihilar Cholangiocarcinoma.
    Matsuyama R; Mori R; Ota Y; Homma Y; Yabusita Y; Hiratani S; Murakami T; Sawada Y; Miyake K; Shimizu Y; Kumamoto T; Endo I
    Ann Surg Oncol; 2022 Apr; 29(4):2393-2405. PubMed ID: 34994885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant hyperfractionated chemoradiation and liver transplantation for unresectable perihilar cholangiocarcinoma in Canada.
    Loveday BPT; Knox JJ; Dawson LA; Metser U; Brade A; Horgan AM; Gallinger S; Greig PD; Moulton CA
    J Surg Oncol; 2018 Feb; 117(2):213-219. PubMed ID: 29480952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perihilar Cholangiocarcinoma: Number of Nodes Examined and Optimal Lymph Node Prognostic Scheme.
    Bagante F; Tran T; Spolverato G; Ruzzenente A; Buttner S; Ethun CG; Groot Koerkamp B; Conci S; Idrees K; Isom CA; Fields RC; Krasnick B; Weber SM; Salem A; Martin RC; Scoggins C; Shen P; Mogal HD; Schmidt C; Beal E; Hatzaras I; Vitiello G; IJzermans JN; Maithel SK; Poultsides G; Guglielmi A; Pawlik TM
    J Am Coll Surg; 2016 May; 222(5):750-759.e2. PubMed ID: 27113512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant therapy reduces node positivity but does not confer survival benefit versus up-front resection for resectable intrahepatic cholangiocarcinoma: A propensity-matched analysis.
    Wehrle CJ; Chang J; Woo K; Gross A; Naples R; Dahdaleh F; Stackhouse K; Kim J; Augustin T; Simon R; Joyce D; Kwon DCH; Miller C; Walsh RM; Aucejo F; Naffouje S
    J Surg Oncol; 2024 Sep; 130(3):453-461. PubMed ID: 39082443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in Prognostic Factors and Recurrence Patterns After Curative-Intent Resection of Perihilar and Distal Cholangiocarcinomas.
    Sallinen V; Sirén J; Mäkisalo H; Lehtimäki TE; Lantto E; Kokkola A; Nordin A
    Scand J Surg; 2020 Sep; 109(3):219-227. PubMed ID: 30791825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the most accurate lymph node staging method for perihilar cholangiocarcinoma? Comparison of UICC/AJCC pN stage, number of metastatic lymph nodes, lymph node ratio, and log odds of metastatic lymph nodes.
    Conci S; Ruzzenente A; Sandri M; Bertuzzo F; Campagnaro T; Bagante F; Capelli P; D'Onofrio M; Piccino M; Dorna AE; Pedrazzani C; Iacono C; Guglielmi A
    Eur J Surg Oncol; 2017 Apr; 43(4):743-750. PubMed ID: 28094085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence after curative-intent resection of perihilar cholangiocarcinoma: analysis of a large cohort with a close postoperative follow-up approach.
    Komaya K; Ebata T; Yokoyama Y; Igami T; Sugawara G; Mizuno T; Yamaguchi J; Nagino M
    Surgery; 2018 Apr; 163(4):732-738. PubMed ID: 29336813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemoradiotherapy before resection of perihilar cholangiocarcinoma: A systematic review.
    Baltatzis M; Jegatheeswaran S; Siriwardena AK
    Hepatobiliary Pancreat Dis Int; 2020 Apr; 19(2):103-108. PubMed ID: 32147487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymph node dissection in resectable perihilar cholangiocarcinoma: a systematic review.
    Kambakamba P; Linecker M; Slankamenac K; DeOliveira ML
    Am J Surg; 2015 Oct; 210(4):694-701. PubMed ID: 26212390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of nodal status for perihilar cholangiocarcinoma: location, number, or ratio of involved nodes.
    Aoba T; Ebata T; Yokoyama Y; Igami T; Sugawara G; Takahashi Y; Nimura Y; Nagino M
    Ann Surg; 2013 Apr; 257(4):718-25. PubMed ID: 23407295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic and Prognostic Role of 18-FDG PET/CT in the Management of Resectable Biliary Tract Cancer.
    Ma KW; Cheung TT; She WH; Chok KSH; Chan ACY; Dai WC; Chiu WH; Lo CM
    World J Surg; 2018 Mar; 42(3):823-834. PubMed ID: 28905105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-grade dysplasia/carcinoma in situ of the bile duct margin in patients with surgically resected node-negative perihilar cholangiocarcinoma is associated with poor survival: a retrospective study.
    Higuchi R; Yazawa T; Uemura S; Izumo W; Furukawa T; Yamamoto M
    J Hepatobiliary Pancreat Sci; 2017 Aug; 24(8):456-465. PubMed ID: 28547855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant hepatic artery resection for advanced perihilar cholangiocarcinoma: a case-control study with propensity score matching.
    Noji T; Tsuchikawa T; Okamura K; Tanaka K; Nakanishi Y; Asano T; Nakamura T; Shichinohe T; Hirano S
    J Hepatobiliary Pancreat Sci; 2016 Jul; 23(7):442-8. PubMed ID: 27207604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma.
    Le Roy B; Gelli M; Pittau G; Allard MA; Pereira B; Serji B; Vibert E; Castaing D; Adam R; Cherqui D; Sa Cunha A
    Br J Surg; 2018 Jun; 105(7):839-847. PubMed ID: 28858392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome and prognostic factors of intrahepatic cholangiocarcinoma involving the hepatic hilus versus hilar cholangiocarcinoma after curative-intent resection: Should they be recognized as perihilar cholangiocarcinoma or differentiated?
    Lu J; Li B; Li FY; Ye H; Xiong XZ; Cheng NS
    Eur J Surg Oncol; 2019 Nov; 45(11):2173-2179. PubMed ID: 31208772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.